Tip I IFN reseptör kompleks
7. NAb pozitif hastaların T2 lezyon hacmi ve kontrast tutan lezyon sayısı temelinde MRG üzerine etkisi olmadığı gösterilmiştir.
Bu çalışma verileri NAb gelişiminin ve interferon yanıtsızlılığının immunogenetik temellerinin araştırılması konusunda yapılacak çalışmalara temel oluşturacak niteliktedir.
63 KAYNAKLAR
1. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 1989;112:133-146. 2. Ebers GC. Natural history of multiple sclerosis. In: Compston A, Ebers GC, editors.
McAlpine‟s Multiple Sclerosis. London: Churchill Livingston, 1998;191-222.
3. Lublin FD, Reingold SC and National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907- 911.
4. Miller AE, Lublin FD, Coyle PK. In: Miller AE. Disease Modifying Therapy. Multilple Sclerosis in Clinical Practice. First Edition. London and New York: Martin Dunitz, 2003;163-183.
5. Pachner AR, Dail D, Pak E et al. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 2005;166:180-188.
6. Malucchi S, Gilli F, Caldano M et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1119-1127.
7. Oger J, Gibbs E. Binding antibodies: Vancouver‟s perspective. Mult Scler 2007;13:36-43. 8. Durelli L, Verdun E, Barbero P et al. Every-other-day interferon beta-1b versus once-
weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60.
9. Polman C, Kappos L, White R et al. European Study Group in Interferon Beta-1b in Secondary Progressive MS: Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003;60:37-43.
10. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study. Neurology 2005;65:40-47.
11. Francis GS, Rice GPA, Alsop JC, for the PRISMS study group Interferon beta-1a in MS. Results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55.
64 12. Hesse D, Sorensen PS. Using measurements of neutralizing antibodies: the challenge if
IFN-beta therapy. Eur J Neurol 2007;14:850-859.
13. Rot U, Sominanda A, Fogdell-Hahn A et al. Impression of clinical worsening fails to predict interferon-beta neutralizing antibody status. J Int Med Res 2008;36:1418-25. 14. Noseworthy JH, Lucchinetti C, Rodriguez M et al. Medical progress: multiple sclerosis.
N Engl J Med 2000;343:938-952.
15. Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacology&Therapeutics 2006;109:198-209.
16. Weiner HL. A shift from adaptive to innate immunity:a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008;255:3-11.
17. Lucchinetti CF,Brück W, Lassmann H. Pathology and Pathogenesis of Multiple Sclerosis. In: McDonald WI, Nosewothy JH. Blue Books of Practical Neurology. Multiple Sclerosis 2. USA: Elsevier Science, 2003;93-115.
18. Charcot JM. Histologie de la sclerose en plague. Gaz Hospital (Paris) 1848;41:554-556. (Kornek B, Lassmann H. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 1999;9:651-656).
19. Charcot JM. Lecons sur les Maladies du Systeme Nerveux Faites a la Salpetriere. In: Delahaye A, Lecrosiew E. Paris: Cerf et fils, 1880;189-220. (Kornek B, Lassmann H. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 1999;9:651-656). 20. Lassmann H, Raine CS, Antel J et al. Immunopathology of multiple sclerosis: report on
an international meeting held at the İnstitute of Neurology of the University of Vienna. J Neuroimmunol 1998;86:213-217.
21. Brück W, Porada P, Poser S et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-796.
22. Rodriquez M, Scheithauer BW. Ultrastructure of multiple sclerosis. Ultrastruct Pathol 1994;18:3-13.
23. Prineas JW, Barnard RO, Revesz T et al. Multiple sclerosis: pathology of recurrent lesions. Brain 1993;116:681-693.
24. Hemmer B, Archelos JJ, Hartung H-P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291-301.
65 25. Giovannoni G, Hartung HP. The immunopathogenesis of multiple sclerosis and Guillain-
Barre syndrome. Curr Opin Neurol 1996;9:165-177.
26. Coyle PK. The neuroimmunology of multiple sclerosis. Adv Neuroimmunol 1996;6:143- 154.
27. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodejenerative disease. Nature Rev Neurosci 2003;4:103-112.
28. Tuohy VK, Yu M, Yin L et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998;164:93-100.
29. Yong VW. Immunopathogenesis of Multiple Sclerosis. In: Miller AE Continuum. Lifelong Learning in Neurology. Mult Scler 2004;11-28.
30. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002;5:463-468.
31. Yong VW, Power C, Forsyth P et al. Metalloproteinases in biology and pathology of the nervous system. Nature Rev Neurosci 2001;2:502-511.
32. Yong VW, Krekoski CA, Forsyth PA et al. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21:75-80.
33. Chandler S, Miller KM, Clements JM et al. Matrix metalloproteinases, tumour necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 1997;72:155-161.
34. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-339
35. Cuzner ML, Gveric D, Strand C et al. The expression of tissue-type plasminogen activator, matrix metalloproteinases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropath Exp Neurol 1996;55:1194-1204.
36. Lee MA, Palace J, Stabler G et al. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999;122:191-197.
37. Yong VW, Chabot S, Stuve O et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-689.
66 38. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J
Neurosci Res 1996;45:322-333.
39. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol 1999;12:309-321.
40. Furuzawa-Caballeda J,Vargas-Rojas MI, Cabral AR. Autoimmune inflamation from the TH17 perspective. Autoimmun Rev. 2007;6(3):169-175.
41. Luchinetti C, Bruck W, Parisi J et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 1999;122:2279-2295.
42. Luchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
43. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115-121.
44. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55(4):458-468.
45. Trap BD, Ransohoff RM, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302.
46. Coleman MP, Perry VH. Axon pathology in neurological disease: a neglected therapeutic agent. Trends Neurosci 2002;25:532-537.
47. Filippi M, Bozzali M, Rovaris M et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-437.
48. Bjartmar C, Trap BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-278.
49. Steinman L. Multiple sclerosis. Nat Immunol 2001;2(9):762–4.
50. Lublin FD. Treatments for multiple sclerosis. In: Miller AE AAN. Continuum. Lifelong Learning in Neurology. Multiple Sclerosis 2004;120-141.
51. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis. New aspects and practical application. J Neurol 2004;251:1329-1339.
52. Weinshenker BG, O‟Brien PC, Petterson TM et al. A randomized trial of plasma Exchange in acute central nervous system inflamatory demiyelinating disease. Ann Neurol 1999;46:878-886.
67 53. Goodin DS. Therapeutic developments in multiple sclerosis. Expert Opin Investig Drugs
2000;9:655-670.
54. Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004;251:12-29.
55. Arnon R. The development of Cop 1 (Copaxone),an innovative drug fort he tretament of multiple sclerosis:personal reflectios. Immunology Letters 1996;50:1-15.
56. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer I to class II major histocompatibility complex molecules on living antigenpresenting cells-specificity and promiscuity. Proc Natl Acad Sci U S A 1994;91:4872-4876.
57. Blanchette F, Neuhaus O. Glatiramer Acetate. Evidence for a dual mechanism of action. J of Neurol. 2008;255:26-36.
58. Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 2003;348:15-23.
59. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004;18(6):379-96.
60. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
61. Hartung HP, Gonsette R, Konig N et al and the Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25.
62. Fernández O. Combination terapy in multiple sclerosis. J of the Neurol Sci 2007;259:95- 103.
63. Kohama I, Lankford KL, Preiningerova J. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J Neurosci 2001;21:944-950.
64. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual defisit in multiple sclerosis. Neurology 2003;61:1528-1532.
65. Tullman M. Symptomatic therapy in multiple sclerosis. In: Miller. Continuum. Lifelong Learning in Neurology. Multiple Sclerosis 2004;142-172.
68 66. IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-
remitting multiple sclerosis.1. Clinical results of a multicenter, randomized, double-blind, plasebo-controlled trail. Neurology 1993;43:655-6.
67. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind plasebo controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504. 68. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon β-1a
treatment regimens in MS: the EVIDENCE trail. Neurology 2002;59:1496-1506.
69. IFNβ Multiple Sclerosis Study Group, University of British Colombia MS/ MRI Analysis Group. Neutralizing antibodies durind treatment of multiple sclerosis with interferon beta- 1b: experience during the first three years. Neurology 1996;47:889-94.
70. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
71. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272. 72. Durelli L, Verdun E, Barbero P et al. Every-other-day interferon beta-1b versus once-
weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60.
73. Jacobs L, O‟Malley J, Feeman A et al. Intrathecal interferon in multiple sclerosis. Arch Neurol 1982;39:609-615.
74. Rudick RA, Ransohoff RM, Peppler R et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40:618-627.
75. Stuve O, Dooley NP, Uhm JH et al. Interferon b-1b decreases the migration of T Lymphocytes in vivo: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853- 863.
76. Martin R. Immunology of Multiple Sclerosis. In: McDonald WI, Noseworthy JH. Blue Books of Practical Neurology. Multiple Sclerosis 2. USA: Elsevier Science 2003;33-59. 77. Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharm &
69 78. Pachner AR. Real-time Taqman assay for myxovirus resistance protein (MxA) mRNA: a robust marker of interferon beta bioactivity in patients with multiple sclerosis. Mult Scler 2007;13:49-52.
79. Giovannoni G, Munschauer III FE, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465-469.
80. Bellomi F, Scagnolari C, Tomassini V et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Scien 2003;215:3-8. 81. Deisenhammer F, Schellekens H, Bertolotto A. Measurement of neutralizing antibodies to
interferon beta in patients with MS. J Neurol. 2004;251:31-39.
82. Gibbs E, MacDonnell G, Deisenhammer F et al.Binding antibodies to Interferon beta during treatment of MS are biologically and clinically relevant. Neurology 2002;58:A72. 83. Arnason BG, Dianzani F. Correlation of the appearance of anti-interferon antibodies
during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies. J Interferon Cytokine Res 1998;18:639–644.
84. Perini P, Clabrese M, Biasi G et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004;251:305-309.
85. Wolinsky JS, Toyka KV, Kappos L et al. Interferon beta antibodies: implications for treatment of MS. Lancet 2003;2:528.
86. Gneiss C, Reindl M, Lutterotti A et al. Interferon beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004;10:507-510.
87. Hemmer B, Stüve O, Kieseier B et al. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005;4:403-412.
88. Kivisakk P, Alm GV, Tian WZ et al. Neutralizing and binding anti-interferon-β-1b (IFN- β-1b) antibodies during IFN-β-1b treatment of multiple sclerosis. Mult Scler 1997;3:184- 190.
89. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-1636.
70 90. Bertolotto A, Gilli F, Sala A et al. Persistent neutralizing antibodies abolish the interferon
β bioavailability in MS patients. Neurology 2003;60:634-639.
91. Von Wussow P, Jakschies D, Hochkeppel HK et al. The human intracellular Mx- homologous protein is specifically induced by type I interferons. Eur J Immunol 1990;20:2015-2019.
92. Von Wussow P, Jakschies D, Block B et al. The interferon-induced Mx-homologous protein in people with symptomatic HIV-1 infection. AIDS 1990;4:119-124.
93. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFN[beta] bioactivity: Detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003;61:24-26.
94. Bertolotto A, Gilli F, Sala A. Evaluation of bioavailability of three types of IFNb in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immun Methods 2001;256:141–152.
95. Sørensen PS, Deisenhammer F, Duda P. Guidelines on use of anti-IFN-b antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-b antibodies in multiple sclerosis. Eur J Neurol 2005;12:817–827.
96. Poser CM, et al. New Diagnostic Criteria for MS: guidelines for research protocol. Ann Neurology 1983;13:227-231.
97. McDonald WI, et al. Recommended Diagnostic Criteria for MS: guidelines from the International Panel on the diagnosis of MS. ANN Neurol 2001;50:121-127.
98. Kurtzke JF. Rating neurologic impairment in multiple scleosis: an expanded status scale (EDSS). Neurology 1983;33:1444-1452.
99. Nagata S, Taira H, Hall A et al. synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980;284:316-20.
100. Deisenhammer Florian. Neutralizing antibodies to Interferon-beta and other Immunological Treatments for Multiple Sclerosis Prevalans and Impacts on Outcomes. CNS Drugs 2009;23(5):379-396.
101. Jacobs LD, Cookfair DL, Rudick RA et al. A phase III trial of intramuscular recombinant interferon beta as treatment of exacerbating-remitting multiple sclerosis: design and conduct of study and baseline charateristics of patients. The Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995;1:118-135.
71 102. Bertolotto A. Implications of neutralising antibodies on therapeutic efficacy. J Neurol
Scien 2009;277:29-32.
103. Ross C, Clemmesen KM, Svenson M et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000;48:706-712.
104. Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003;61:6-10. 105. Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines – friends or
foes? Immunol Today 1990;11:167-169.
106. Gneiss C, Tripp P, Ehling R et al. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies. J Neuroımmunol 2006;174:174-179.
107. Gneiss C, Reindl M, Berger T et al. Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res 2004;24:283-90.
108. Pachner AR, Oger J, Place J. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. Neurology 2003;61:18-20.
109. Gneiss C, Brugger M, Millonig A et al. Comparative study of four different assays for the detection of binding antibodies against interferon-β. Mult. Scler. 2008;14:830–836. 110. Aarskog NK, Marøy T , Myhr K-M et al. Antibodies against interferon-beta in multiple
sclerosis. J of neuroimmunol 2009;212:148-150.
111. Gilli F, Marnetto F, Caldano M et al. Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. J Neuroimmunol 2007;192:198-205.
112. Sorensen PS. Neutralizing antibodies against interferon beta. The Therapeutic Advances in Neurological Disorders 2008;1:125-141.
113. Pachner AR, Brady J, Steiner I, Narayan K: Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients. J Neurol 2008;255:1815- 1817.
114. Deisenhammer F, Reindl M, Harvey J et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
115. Deisenhammer F, Mayringer I, Harvey J, Dilitz E. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 2000;54:2055-2060.
72 116. Kracke A, von Wussow P, Al Masri AN et al. Mx proteins in blood leukocytes for
monitoring interferon beta-1b therapy in patients with MS. Neurology 2000;54:193-99. 117. Gilli F, Marnetto F, Caldano M et al. Biological responsiveness to first injections of
interferon-beta in patients with multiple sclerosis. J Neuroimmunol 2005;158:195-203. 118. Bertolotto A, Sala A, Caldano M et al. Development and validation of a real time PCR-
based bioassay for quantification of neutralizing antibodies against human interferon-beta. J immunol Methods 2007;321:19-31.
119. Hesse D, Sellebjerg F, Sorensen SP. Absence of MxA induction by interferon in patients with MS reflects complete loss of bioactivity. Neurology 2009;73:372-377.
120. Pachner A, Narayan K, Price N. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibodymediated decreased bioactivity. Mol. Diagn. 2003;7:17-25.
121. Gilli F, Marnetto F, Stefanuto G et al. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol Diagn 2004;8:185-194.
122. Pachner AR, Warth JD, Pace Amy et al. Effect of antibodies on biomarker response to interferon beta: The INSIGHT study. Neurology 2009;73:1493-1500.
123. Vartanian TK, Sorensen PS, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol 2004;251:25-30.
124. Vartanian TK, Zamvil SS, Fox E. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 2004;63:42-49.
125. Schellekens H. Bioequivalence and the ımmunogenecity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-462.
126. Gneiss C, P Tripp P, Reichartseder F. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Multiple Sclerosis 2006;12:731-737. 127. Malucchi S, Sala A, Gilli F. Neutralizing antibodies reduce the efficacy of IFN during
treatment of multiple sclerosis. Neurology 2004;62:2031-2037.
128. Sominanda A, Rot U, Suoniemi M et al. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalance and immunogenecity. Mult Scler 2007;13:208-214.
73 129. Sorensen PS, Ross C, Clemmesen KM et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191.
130. Rice GPA, Paszner B, Oger J et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferonβ-1b. Neurology 1999;52:1277-1279.
131. Kivisakk P, Alm GV, Fredrikson S et al. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 2000;7:27-34.
132. Sorensen PS, Koch-Henriksen N, Ross C et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39.
133. van der Meide PH, Schellekens H. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy 1997;10:39-48.
134. Gneiss C, Koudouovoh-Tripp PM, Ropele S et al. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Australian Switch Study. Mult Scler 2009;15:1481-1488.
135. Bertolotto A, Deisenhammer F, Gallo P et al. Immunogenicity of interferon beta: differences among products. J Neurol 2004;251:14-24.
136. Hoffmann S, Cepok S, Grummel V HLA-DRB1*0401 and HLA-DRB1*0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis. AJHG 2008;73:1485-1492.
137. Larocco AP, Leung SC, Marcus SG et al. Evaluation of neutralizing antibodies in patients with recombinant interferon-beta J Interferon Res 1989;9:51-60.
138. Pachner AR, Cadavid D, Wolansky L et al. Effect of anti-IFNβ antibodies on MRI
lesions of MS patients in the BECOME study
Neurology 2009;73:1485-1492.
139. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis. A follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148–153.
140. Antonelli G, Bagnato F, Pozzilli C et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFNβ-1a. J Interferon Cytokine Res 1998;18:345-350.
74 141. Antonelli G, Simeoni E, Bagnato F et al. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Scien 1999;168:131-136. 142. Scagnolari C, Bellomi F, Turriziani O et al. Neutralizing and binding antibodies to IFN-
β. Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations. J Interferon Cytokine Res 2002;22:207–213.
143. Giovannoni G, Munschauer FE, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465 9.
144. Hartung H-P, Munschauer F, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the proceedings of an international consensus conference. Eur J Neurol 2005;12:588–601. 145. Boz C, Oger J, Gibbs E. Reduced effectiveness of long-term interferon-β treatment on
relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Multiple Sclerosis 2007;13:1127-1137.
146. Frank JA, Richert N, Bash C et al. Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology 2004;62:719-725. 147. Baarsen LGM, Vosslamber S, Tijssen M et al. Pharmacogenomics of interferon-beta
therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 2008;3:1927.
148. Gilli F, Valentino P, Caldano M et al. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology 2008;71:1940-7. 149. Petkau AJ, White RA, Ebers GC et al. Longitudinal analyses of the effects of
neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-138.
150. Farrell RA, Giovannoni G. Measuring and management of Anti-interferon Beta Antibodies in subjects with Multiple Sclerosis. Mult Scler 2007;13:567-577.
151. Goodin DS, Frohman EM, Hurwitz B et al. Neutralizing antibodies to interferon beta: